Wilson Sonsini Litigation partner Tarek Helou will co-present “Managing the Risks of Government-Run Healthcare Systems: Mitigating Global Corruption and More Potential Exposure in Drug and Device Research, Testing and Approvals in Foreign Jurisdictions” on Thursday, May 8 at 3 p.m. EST at American Conference Institute’s (ACI) 20th Annual FCPA & Anti-Corruption for the Life Sciences Industry event. Topics include:

• Understanding where the biggest vulnerabilities lie in drug and device research and testing within government-run healthcare systems
• Best practices for monitoring and mitigating risks associated with clinical research and trials in foreign jurisdictions
• Navigating the blurred lines of what qualifies as “improper influence” of clinical investigators, ethics committee members, trial data results and the approval process
•  Safeguarding against unique corruption risks associated with clinical trial funding, patient recruitment, the informed consent process, and dealings with third-party research organizations / CROs

The two-day program will provide insights on how life sciences companies are navigating global ethics and compliance amid seismic enforcement shifts, including reassessing industry-specific risks, strengthening internal controls, training, policies, and global anti-corruption compliance.